MedTrace Logo

Transdermal Estrogen in Women With Anorexia Nervosa

NCT03875378 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-05-18

No results posted yet for this study

Summary

Randomized, placebo-controlled study investigating the use of physiologic, transdermal estrogen for low bone mass in adult women with anorexia nervosa.

Conditions

  • Anorexia Nervosa

Interventions

DRUG

Transdermal estrogen

Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch

DRUG

Placebos

Placebo weekly patch

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • Pouneh K. Fazeli, MD

    lead OTHER

Principal Investigators

  • Pouneh Fazeli, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-28
Primary Completion
2028-08-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03875378 on ClinicalTrials.gov